Development and validation of prediction model for overall survival in patients with lymphoma: a prospective cohort study in China

Abstract Objective The survival of patients with lymphoma varies greatly among individuals and were affected by various factors. The aim of this study was to develop and validate a prognostic model for predicting overall survival (OS) in patients with lymphoma. Methods We conducted a prospective lon...

Full description

Bibliographic Details
Main Authors: Xiaosheng Li, Yue Chen, Anlong Sun, Ying Wang, Yao Liu, Haike Lei
Format: Article
Language:English
Published: BMC 2023-07-01
Series:BMC Medical Informatics and Decision Making
Subjects:
Online Access:https://doi.org/10.1186/s12911-023-02198-0
_version_ 1797774181102780416
author Xiaosheng Li
Yue Chen
Anlong Sun
Ying Wang
Yao Liu
Haike Lei
author_facet Xiaosheng Li
Yue Chen
Anlong Sun
Ying Wang
Yao Liu
Haike Lei
author_sort Xiaosheng Li
collection DOAJ
description Abstract Objective The survival of patients with lymphoma varies greatly among individuals and were affected by various factors. The aim of this study was to develop and validate a prognostic model for predicting overall survival (OS) in patients with lymphoma. Methods We conducted a prospective longitudinal cohort study in China between January 2014 and December 2018 (n = 1,594). After obtaining the follow-up data, we randomly split the cohort into the training cohort (n = 1,116) and the validation cohort (n = 478). The least absolute shrinkage and selection operator (LASSO) regression analysis was used to select the predictors of the model. Cox stepwise regression analysis was used to identify independent prognostic factors, which were finally displayed as static nomogram and web-based dynamic nomogram. We calculated the concordance index(C-index) to describe how the predicted survival of objectively confirmed prognosis. The calibration plot is used to evaluate the prediction accuracy and discrimination ability of the model. Net reclassification index (NRI) and decision curve analysis (DCA) curves were also used to evaluate the prediction ability and net benefit of the model. Results Nine variables in the training cohort were considered to be independent risk factors for patients with lymphoma in the final model: age, Ann Arbor Stage, pathologic type, B symptoms, chemotherapy, targeted therapy, lactate dehydrogenase (LDH), β2-microglobulin and C-reactive protein (CRP). The C-indices of OS were 0.749 (95% CI, 0.729–0.769) in the training cohort and 0.731 (95% CI, 0.762–0.700) in the validation cohort. A good agreement between prediction by nomogram and actual observation was shown in the calibration curve for the probability of survival in both the training cohort and validation cohorts. The areas under curve (AUC) of the area under the receiver operating characteristic (ROC) curves for 1-year, 3-year, and 5-year OS were 0.813, 0.800, and 0.762, respectively, in the training cohort, and 0.802, 0.768, and 0.721, respectively, in the validation cohort. Compared with the Ann Arbor Stage system, NRI and DCA showed that the model had a higher predictive capacity and net benefit. Conclusion The prediction models reliably estimate the outcome of patients with lymphoma. The model had high discrimination and calibration, which provided a simple and reliable tool for the survival prediction of the patients, and it might help patients benefit from personalized intervention.
first_indexed 2024-03-12T22:17:17Z
format Article
id doaj.art-d6192e43b765462eb8e4139ab1e264af
institution Directory Open Access Journal
issn 1472-6947
language English
last_indexed 2024-03-12T22:17:17Z
publishDate 2023-07-01
publisher BMC
record_format Article
series BMC Medical Informatics and Decision Making
spelling doaj.art-d6192e43b765462eb8e4139ab1e264af2023-07-23T11:16:27ZengBMCBMC Medical Informatics and Decision Making1472-69472023-07-0123111110.1186/s12911-023-02198-0Development and validation of prediction model for overall survival in patients with lymphoma: a prospective cohort study in ChinaXiaosheng Li0Yue Chen1Anlong Sun2Ying Wang3Yao Liu4Haike Lei5Chongqing Cancer Multi-omics Big Data Application Engineering Research Center, Chongqing University Cancer HospitalChongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer HospitalChongqing Cancer Multi-omics Big Data Application Engineering Research Center, Chongqing University Cancer HospitalChongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer HospitalChongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer HospitalChongqing Cancer Multi-omics Big Data Application Engineering Research Center, Chongqing University Cancer HospitalAbstract Objective The survival of patients with lymphoma varies greatly among individuals and were affected by various factors. The aim of this study was to develop and validate a prognostic model for predicting overall survival (OS) in patients with lymphoma. Methods We conducted a prospective longitudinal cohort study in China between January 2014 and December 2018 (n = 1,594). After obtaining the follow-up data, we randomly split the cohort into the training cohort (n = 1,116) and the validation cohort (n = 478). The least absolute shrinkage and selection operator (LASSO) regression analysis was used to select the predictors of the model. Cox stepwise regression analysis was used to identify independent prognostic factors, which were finally displayed as static nomogram and web-based dynamic nomogram. We calculated the concordance index(C-index) to describe how the predicted survival of objectively confirmed prognosis. The calibration plot is used to evaluate the prediction accuracy and discrimination ability of the model. Net reclassification index (NRI) and decision curve analysis (DCA) curves were also used to evaluate the prediction ability and net benefit of the model. Results Nine variables in the training cohort were considered to be independent risk factors for patients with lymphoma in the final model: age, Ann Arbor Stage, pathologic type, B symptoms, chemotherapy, targeted therapy, lactate dehydrogenase (LDH), β2-microglobulin and C-reactive protein (CRP). The C-indices of OS were 0.749 (95% CI, 0.729–0.769) in the training cohort and 0.731 (95% CI, 0.762–0.700) in the validation cohort. A good agreement between prediction by nomogram and actual observation was shown in the calibration curve for the probability of survival in both the training cohort and validation cohorts. The areas under curve (AUC) of the area under the receiver operating characteristic (ROC) curves for 1-year, 3-year, and 5-year OS were 0.813, 0.800, and 0.762, respectively, in the training cohort, and 0.802, 0.768, and 0.721, respectively, in the validation cohort. Compared with the Ann Arbor Stage system, NRI and DCA showed that the model had a higher predictive capacity and net benefit. Conclusion The prediction models reliably estimate the outcome of patients with lymphoma. The model had high discrimination and calibration, which provided a simple and reliable tool for the survival prediction of the patients, and it might help patients benefit from personalized intervention.https://doi.org/10.1186/s12911-023-02198-0Lymphoma patientsPrognosisSurvivalPrediction model
spellingShingle Xiaosheng Li
Yue Chen
Anlong Sun
Ying Wang
Yao Liu
Haike Lei
Development and validation of prediction model for overall survival in patients with lymphoma: a prospective cohort study in China
BMC Medical Informatics and Decision Making
Lymphoma patients
Prognosis
Survival
Prediction model
title Development and validation of prediction model for overall survival in patients with lymphoma: a prospective cohort study in China
title_full Development and validation of prediction model for overall survival in patients with lymphoma: a prospective cohort study in China
title_fullStr Development and validation of prediction model for overall survival in patients with lymphoma: a prospective cohort study in China
title_full_unstemmed Development and validation of prediction model for overall survival in patients with lymphoma: a prospective cohort study in China
title_short Development and validation of prediction model for overall survival in patients with lymphoma: a prospective cohort study in China
title_sort development and validation of prediction model for overall survival in patients with lymphoma a prospective cohort study in china
topic Lymphoma patients
Prognosis
Survival
Prediction model
url https://doi.org/10.1186/s12911-023-02198-0
work_keys_str_mv AT xiaoshengli developmentandvalidationofpredictionmodelforoverallsurvivalinpatientswithlymphomaaprospectivecohortstudyinchina
AT yuechen developmentandvalidationofpredictionmodelforoverallsurvivalinpatientswithlymphomaaprospectivecohortstudyinchina
AT anlongsun developmentandvalidationofpredictionmodelforoverallsurvivalinpatientswithlymphomaaprospectivecohortstudyinchina
AT yingwang developmentandvalidationofpredictionmodelforoverallsurvivalinpatientswithlymphomaaprospectivecohortstudyinchina
AT yaoliu developmentandvalidationofpredictionmodelforoverallsurvivalinpatientswithlymphomaaprospectivecohortstudyinchina
AT haikelei developmentandvalidationofpredictionmodelforoverallsurvivalinpatientswithlymphomaaprospectivecohortstudyinchina